Loading...
Market
When will Judo Bio's first kidney RNA drug reach the market?
2
Resolution / Starting Odds
Before 2026 • 25%
2026 • 25%
2027 • 25%
2028 or later • 25%
FDA approval announcements or company press releases
Story
Judo Bio Launches with $100M to Develop RNA Kidney Drugs Using STRIKE Platform
Oct 7, 2024, 12:16 PM
Judo Bio has debuted with a $100 million launch, aiming to develop RNA drugs targeting the kidney. The company plans to utilize its Selectively Targeting RNA Into KidnEy (STRIKE) platform to develop ligand-siRNA conjugates. The launch comes less than two months after Borealis Bio's $150 million launch for similar RNA kidney drugs. Judo Bio's leadership includes CEO Rajiv Patni and CSO Alfica Sehgal, with backing from Atlas Venture and TCG. The company is taking a page from Alnylam's playbook and is part of the broader startups ecosystem.
View original story
Similar markets
Q1 2025 • 25%
Q2 2025 • 25%
Q3 2025 • 25%
Q4 2025 • 25%
Yes • 50%
No • 50%
Before June 30, 2025 • 25%
Between July 1, 2025 and September 30, 2025 • 25%
Between October 1, 2025 and December 31, 2025 • 25%
After December 31, 2025 • 25%
Roche • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
Safety warning update • 25%
Clinical trial halt • 25%
No action • 25%
Other action • 25%
Accelerated Approval • 25%
Full Approval • 25%
Conditional Approval • 25%
No Approval • 25%
Q1 2026 • 25%
Q2 2026 • 25%
Q3 2026 • 25%
Q4 2026 or later • 25%
ARO-DUX4 • 25%
ARO-MMP7 • 25%
Other program • 25%
No program reaches Phase 2 • 25%
Q4 2024 • 25%
Q1 2025 • 25%
Q2 2025 • 25%
Later • 25%